Younger postmenopausal patients with early-stage breast cancer may be able to safely omit adjuvant radiotherapy

Almost all postmenopausal patients aged 50-–69 years with stage I hormone receptor (HR)-positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease free five years after surgery, according to results from the IDEA clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5–9, 2023.